We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




Lithoplasty System Treats Peripheral Artery Disease

By HospiMedica International staff writers
Posted on 18 Jan 2015
Print article
Image: The Lithoplasty balloon catheter system (Photo courtesy of Shockwave Medical).
Image: The Lithoplasty balloon catheter system (Photo courtesy of Shockwave Medical).
A novel system combines the calcium disrupting power of lithotripsy with the simplicity of a balloon catheter into a single device.

The Lithoplasty system is designed to disrupt and pretreat calcium deposits present in peripheral artery disease (PAD) by applying a brief series of powerful mechanical pulses through the soft tissue. The plaque, having been stressed from the induced vibrations, thus becomes more pliable. The integrated balloon catheter is then dilated at low pressures to expand the lesion evenly without damaging the vessels themselves, minimizing any potential acute soft tissue injury that could lead to the need for additional interventional treatments or long-term restenosis.

The balloon dilatation catheter incorporates tiny lithotripsy electrodes that increase the compliance of rigid vascular and valvular lesions prior to the low-pressure dilation. The pretreatment enables more effective angioplasty, less frequent bailout stent usage, and enhanced lesion preparation. In aortic valves, the technology could vastly improve native tissue preparation prior to trans-catheter aortic valve replacement (TAVR) and valvuloplasty for patients not suitable for TAVR. The Lithoplasty system is a product of Shockwave Medical (Fremont, CA, USA), and has received the European Community CE marking of approval.

“CE Mark approval for Lithoplasty in peripheral artery disease is an exciting milestone for Shockwave Medical and sets the stage for regulatory approvals in other geographies,” said Daniel Hawkins, co-founder of Shockwave Medical. “We are also investigating applying this therapy to calcified coronary lesions, another important unmet clinical need.”

“Lithoplasty is a breakthrough that could revolutionize the treatment of peripheral artery disease, a common circulatory problem that can lead to serious complications, including amputation,” said Marianne Brodmann, MD, of the Medical University of Graz (Austria). “With Lithoplasty, even historically very challenging PAD patients with deep calcium can be treated effectively without significant injury to the vessel.”

Related Links:

Shockwave Medical
Medical University of Graz


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
12-Channel ECG
CM1200B
New
Body Composition Analyzer
seca mBCA Pro
New
Total Ankle Prosthesis
SALTO TALARIS

Print article

Channels

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.